London Stock Exchange Welcomes Verici Dx plc to AIM
London Stock Exchange welcomes Verici Dx plc (‘Verici Dx’ or the ‘Company’), a developer of advanced clinical diagnostics for organ transplant, to celebrate the listing of the Company's public shares onto AIM, under the ticker "VRCI".
Verici Dx is an immuno-diagnostics development company, initially focused on the kidney transplantation market. The Company's kidney transplant assays will use advanced next-generation sequencing that may define a personalised risk profile of each patient over the course of their transplant journey and may also detect injury in advance of currently available clinical tests.
The Company develops tests to understand how a patient is likely to, and may be, responding to kidney transplant. There are two leading products for clinical validation and commercialisation:
• Clarava™, which is a pre-transplant prognosis for the risk of early acute rejection; and
• Tuteva™, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatinine levels.
Verici Dx raised £14.5m gross significantly oversubscribed fundraising with net proceeds being used to undertake clinical utility and validation studies, to bioinformatics and health economic studies as well as staff and related benefits, for general corporate overheads and for license and royalties and capital expenditure (including to build additional testing capacity).
Sara Barrington, CEO of Verici Dx, said: “We are very grateful for the strong support shown by institutional and other investors to the Verici Dx IPO. Obtaining funding in a public market is a strong signal of quality to prospective partners and customers, raises the profile of the business and its innovative products considerably, and gives us a supportive platform as we advance our strategy. We look forward to providing further updates on the execution of our validation and commercialisation plans as we deploy the capital raised towards addressing a significant unmet clinical need.”
To find out more about Verici Dx visit: www.vericidx.com